Skip to content

Brian Rush

17 papers in the library · 145 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Policy pathways and historical insights: Canada's evolving approach to psychedelic access for end-of-life distress

International Journal of Drug Policy July 6, 2026 Sarah Kratina, Robert Schwartz, Carol Strike et al.

Canada's evolving attitudes toward psychedelic interventions in palliative and end-of-life care reflect a departure from historically prohibitionist policies and an emerging recognition of their therapeutic potential for individuals facing end-of-life distress. This shift parallels international regulatory developments in jurisdictions such as the United States, Australia and parts of Europe,...

A scoping review of variations in psychedelic interventions for psychological suffering associated with the end of life.

Social science & medicine (1982) February 1, 2026 Sarah Kratina, Carol Strike, Robert Schwartz et al.

Psychedelic substances are recognized for their potential to ease psychological suffering linked to end-of-life issues, yet policy remains restrictive. The wide range of both substances and therapeutic approaches used in end-of-life populations has not been adequately covered by reviews to date. To identify and learn from the variety that exists within the research on therapeutic psychedelic...

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.

Journal of psychopharmacology (Oxford, England) January 30, 2026 Veronica Magar, Marlena Robbins, Óscar Martín López Fernández Lobo Blanco et al. 1 citation

Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across generations, yet their long-standing contributions have often been marginalized through extractive research, commercialization, and policy exclusion. It is Indigenous communities that have stewarded and gained expertise working with psychoactive...

Examining the Perspectives of Key Stakeholders on the Problems, Policies, and Politics Regarding Accessing Psychedelic Interventions to Alleviate End‐of‐Life Distress

Politics &amp Policy January 24, 2026 Sarah Kratina, Robert Schwartz, Carol Strike et al. 2 citations

ABSTRACT Psychedelic interventions are not publicly available through Canada's healthcare system. Despite growing scientific evidence, public interest, and efforts to expand access to psychedelic therapies for end‐of‐life psychological suffering, Canadian policies remain restrictive. Efforts are underway to expand access, but knowledge gaps exist regarding the policy landscape in Canada. This...

Making sense of desperation for treatment in decisions to use psychedelics for depression and anxiety: A qualitative Subreddit study anticipating clinical challenges.

General Hospital Psychiatry 2026 David T. Kryszajtys, Carol Strike, Brian Rush et al. 1 citation

Some individuals interpret persistent depression and anxiety, alongside the exhaustion of standard treatment options, as leading to a desperate need for relief. While desperation may shape how people assess treatment options, its role in psychedelic self-treatment and its relevance for emerging clinical models of psychedelic treatment remain underexplored. We collected discussion threads from...

Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature.

Substance use & addiction journal 2026 Olivia Marcus, Brian Rush

There is an increasing interest in the use of psychedelics for the treatment of substance use disorders (SUDs) and to improve overall health and wellbeing. We aimed to update and complement research syntheses that have focused only on results from clinical trials by synthesizing the research across diverse methods to discuss implications from a broad and multi-faceted literature. We conducted a...

Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico

Journal of Psychedelic Studies January 24, 2025 Cecile Giovannetti, Anja Loizaga-Velder, Ricardo Campoy Gomez et al. 5 citations

Abstract Background The Yaqui Intercultural Medicine Clinic was established in 2020 to provide accessible, culturally-attuned treatment for substance use and mental health disorders among an Indigenous Yaqui community in Mexico. The treatment program integrates ayahuasca ceremonies and psychotherapeutic support within a community-based outpatient treatment service. This observational pilot...

A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.

PLoS One 2025 Sarah Kratina, Carol Strike, Robert Schwartz et al. 1 citation

Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their...

Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science.

Journal of Studies on Alcohol and Drugs September 1, 2024 Brian Rush, Olivia Marcus, Sara García et al. 12 citations

This article focuses on the outcomes at 1 year post-treatment of a naturalistic evaluation of services provided through the Takiwasi Centre, an accredited Peruvian therapeutic community offering an ayahuasca-assisted, integrative treatment program for addiction rehabilitation. Participants (n = 52) completed structured interviews and a battery of validated instruments. Outcome measures included...

Navigating the “Psychedelic Renaissance”: From Research to Reality

International Journal of Mental Health and Addiction April 1, 2024 Doris Payer, Sukhpreet Klaire, Dominique Morisano et al. 4 citations

The field of psychedelics is in an important era, with a significant focus on the potential role of psychedelic compounds in the treatment of mental health and substance use disorders. In 2022, a scientific research conference was held in Toronto to bring together stakeholders from a variety of disciplines and to promote dialogue and collaboration. This Special Issue includes 8 papers based on...

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

International Journal of Mental Health and Addiction April 1, 2024 David T. Kryszajtys, Jacqueline L. Bender, Brian Rush et al. 2 citations

Little is known about how people decide to use psychedelics to self-treat depression and anxiety, though the practice is growing. We explored online community discussions of members’ decisions around self-treatment with psychedelics for depression or anxiety. We used constructivist grounded theory to select and analyze 98 members’ posts across 95 discussion threads (99, 552 words) and...

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues

October 27, 2023 Sarah Kratina, Christopher Lo, Robert Schwartz et al. preprint

ABSTRACTBackground: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with...

Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion.

Healthcare policy = Politiques de sante May 1, 2023 Sarah Kratina, Christopher Lo, Carol Strike et al. 8 citations

In Canada, the conversation to enable access to therapeutic psychedelics is under way. With recent federal initiatives, Canadians can request access to psychedelic-assisted therapies (PATs) to alleviate enduring and intolerable psychological suffering (EIPS) associated with life-threatening conditions on a case-by-case basis. The resurgence of past research concerning the therapeutic potential...

Therapeutic Effects of Ceremonial Ayahuasca Use for Methamphetamine Use Disorders and Other Mental Health Challenges: Case Studies in an Indigenous Community in Sonora, Mexico.

Journal of Psychoactive Drugs 2023 Anja Loizaga-Velder, Cecile Giovannetti, Ricardo Campoy Gomez et al. 9 citations

This paper describes three case studies from an outpatient intercultural therapeutic program founded and run by Yaqui health professionals and traditional healers to serve members of the Yaqui tribe residing in Sonora, Mexico. This pilot therapeutic program has been designed specifically for Indigenous individuals, incorporating the ceremonial use of naturally derived psychedelics in addressing...

Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center

Frontiers in Pharmacology May 19, 2021 Brian Rush, Olivia Marcus, Sara Mallén García et al. 26 citations

The present study describes the protocol for the Ayahuasca Treatment Outcome Project (ATOP) with a special focus on the evaluation of addiction treatment services provided through Takiwasi Center, the first ATOP study site. The goal of the project is to assess treatment outcomes and understand the therapeutic mechanisms of an Ayahuasca-assisted, integrative treatment model for addiction...

Pilot Evaluation of a Residential Drug Addiction Treatment Combining Traditional Amazonian Medicine, Ayahuasca and Psychotherapy on Depression and Anxiety

Journal of Psychoactive Drugs August 4, 2020 Cecile Giovannetti, Sara García Arce, Brian Rush et al. 55 citations

Recent research highlighted the therapeutic potential of ayahuasca, a psychoactive plant brew used ritually in traditional Amazonian medicine (TAM). The present study evaluates the impact of integrating ayahuasca and TAM with psychotherapy on depression and anxiety in an inpatient addiction treatment program. Male patients (N = 31) were evaluated pre and post treatment using the Beck Anxiety...

Who Turns to Amazonian Medicine for Treatment of Substance Use Disorder? Patient Characteristics at the Takiwasi Addiction Treatment Center

Journal of Studies on Alcohol and Drugs July 1, 2020 Ilana Berlowitz, Heinrich Walt, Christian Ghasarian et al. 19 citations

Our results suggest that the Amazonian medicine-based therapy attracts a diverse patient group not limited to regional residents and may be particularly appealing to more impaired SUD patients with a history of unsuccessful treatment. The sample's cultural diversity suggests an existing interest in such therapies among international SUD treatment-seeking patients. These findings are relevant in...